The news last week that a Phase 3 trial of Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug — marketed as Relyvrio — failed to benefit patients compared to placebo hit the ALS patient community hard.
An earlier study had shown that patients who took the drug for six months experienced significantly less decline than people on the placebo in physical function, such as the ability to speak, use utensils, or climb stairs. But while the Phase 2 results led to the drug’s approval by the Food and Drug Administration in 2022, they failed to replicate in a larger group.
Click this link for the original source of this article.
Author: Annalisa Merelli
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.